On August 19, 2026, Merck and Moderna announced that a personalized mRNA cancer vaccine — built individually from each patient’s own tumor — met its goals in a 1,137-patient Phase 3 melanoma trial. Moderna’s stock nearly tripled in a day. But this is not a preventive shot: it is a post-surgery treatment that teaches the immune system to hunt down whatever cancer cells remain. Starting from the basics — what a vaccine actually does, why cancer vaccines failed for decades, and what “the Phase 3 wall” means — we unpack why the market priced in something much bigger than one melanoma drug: a shift from choosing finished medicines to building one per patient. We also translate how Japan reacted, where the story spread as market news first.
※The size of the effect and overall survival data are not yet published, and the trial is ongoing. This is not the moment to say “cancer is cured.” Japanese reactions are translated summaries of posts on X and do not represent Japanese public opinion at large.
Full article: https://sekahan0623.com/en/global-reactions-en/personalized-mrna-cancer-vaccine-melanoma/
X (Twitter): https://x.com/sekahan_0623
This program is produced with synthesized narration (Voice: Google Cloud Text-to-Speech (Chirp 3: HD)).
